A Phase 3 interventional study of Cicatrix and Placebo in Post-surgical Scars, sponsored by Catalysis SL. Completed at 1 site in Cuba. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2010-12-08.
Sponsored by Catalysis SL · Phase 3, Interventional, and Treatment
The purpose of the study is to assess the efficacy of CICATRIX (Asian Gotu Kola or Pennywort) usage in the treatment of recent post-surgical scars. The duration of this double-blind placebo controlled phase 3 clinical trial will be 4 weeks. The estimated number of persons to be recruited and randomized for the study is 90.
307 studies on the registry are indexed under Cicatrix; 50 are open to participants now.
This study's planned enrollment of 90 is above the median of 39 across 251 interventional studies indexed under Cicatrix.
Browse Cicatrix studies →Catalysis SL is the lead sponsor of 52 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Cicatrix
Other: Cicatrix
Placebo
Other: Placebo
Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
Also known as: Cosmetic
Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
Length of the post-surgical scar(s) measured by a millimetric ruler at week 4 (end of the treatment)
Time frame: 4 weeks
Occurrence of adverse effects at week 4 (end of the treatment)
Time frame: 4 weeks
Photographs of lesions at week 4 (end of the treatment)
Time frame: 4 weeks
This study is completed, as verified in Dec 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Catalysis SL